Since August 2011, Caragol served at PositiveID as chief executive officer (CEO) and as president since May 2007.
PositiveID chairman William Caragol said the company has a number of opportunities ahead such as marketing FDA cleared iglucose, the continued development of their non-invasive diabetes management products, and high-value opportunities within their subsidiary, MicroFluidic Systems, including a potential $3bn BioWatch procurement.
"The Board and executive management team will continue to focus on these opportunities to grow PositiveID and create meaningful revenue and deliver stockholder value," Caragol added.
